跳转至内容
Merck
CN

A0200000

乙酰水杨酸

European Pharmacopoeia (EP) Reference Standard

别名:

2-乙酰氧基苯甲酸, O-乙酰水杨酸, ASA, 阿司匹林

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

线性分子式:
2-(CH3CO2)C6H4CO2H
化学文摘社编号:
分子量:
180.16
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
779271
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


grade

pharmaceutical primary standard

API family

aspirin

manufacturer/tradename

EDQM

mp

134-136 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CC(=O)Oc1ccccc1C(O)=O

InChI

1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)

InChI key

BSYNRYMUTXBXSQ-UHFFFAOYSA-N

Gene Information

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Acetylsalicylic acid EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

通过抑制环氧化酶(前列腺素H合酶),对COX-1亚型具有更高的选择性,阻止前列腺素的产生。抗血栓作用是由于COX-1在血小板中的抑制作用,阻止血栓形成和血小板聚集。 对结直肠及其他实体肿瘤有化学预防作用。

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.


Still not finding the right product?

Explore all of our products under 乙酰水杨酸


pictograms

Exclamation mark

signalword

Warning

存储类别

11 - Combustible Solids

wgk

WGK 1

flash_point_f

482.0 °F

flash_point_c

250 °C

hcodes

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 3



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Christina Perneby et al.
Thrombosis and haemostasis, 95(4), 652-658 (2006-04-08)
Aspirin is widely used, but dosages in different clinical situations and the possible importance of "aspirin resistance" are debated. We performed an open cross-over study comparing no treatment (baseline) with three aspirin dosage regimens--37.5 mg/day for 10 days, 320 mg/day
A O Maree et al.
Journal of thrombosis and haemostasis : JTH, 3(10), 2340-2345 (2005-09-10)
Aspirin (acetylsalicylic acid) irreversibly inhibits platelet cyclooxygenase (COX)-1, the enzyme that converts arachidonic acid (AA) to the potent platelet agonist thromboxane (TX) A2. Despite clear benefit from aspirin in patients with cardiovascular disease (CAD), evidence of heterogeneity in the way
Andrew O Maree et al.
Journal of the American College of Cardiology, 46(7), 1258-1263 (2005-10-04)
We investigated whether use of low-dose enteric-coated (EC) aspirin for secondary prevention of cardiovascular events has sufficient bioavailability to achieve complete platelet cyclooxygenase (COX) inhibition in all individuals. Aspirin reduces cardiovascular morbidity and mortality in patients with pre-existing vascular disease;



全球贸易项目编号

货号GTIN
A020000004061833327104